174 related articles for article (PubMed ID: 3092893)
1. The oestrogenic effects of ethinyl oestradiol/polyoestradiol phosphate and estramustine phosphate in patients with prostatic carcinoma. A comparative study of oestrogen sensitive liver proteins, gonadotrophins and prolactin.
Daehlin L; Damber JE; von Schoultz B; Bergman B
Br J Urol; 1986 Aug; 58(4):412-6. PubMed ID: 3092893
[TBL] [Abstract][Full Text] [Related]
2. Some effects of treatment with ethinyl oestradiol with or without polyoestradiol phosphate in patients with prostatic carcinoma.
Tomić R
Scand J Urol Nephrol; 1986; 20(3):193-6. PubMed ID: 3097813
[TBL] [Abstract][Full Text] [Related]
3. On the effects of oestrogen in the male. Some effects of different oestrogenic substances in rats and men with prostatic carcinoma.
Daehlin L
Scand J Urol Nephrol Suppl; 1985; 91():1-44. PubMed ID: 3868029
[TBL] [Abstract][Full Text] [Related]
4. Effects of ethinyl oestradiol/polyoestradiol phosphate and estramustine phosphate on some proteins related to haemostasis in prostatic carcinoma patients.
Damber JE; Daehlin L; Tomic R; Nilsson TK
Int Urol Nephrol; 1991; 23(3):251-6. PubMed ID: 1889971
[TBL] [Abstract][Full Text] [Related]
5. Treatment of prostatic carcinoma with various types of estrogen derivatives.
Jönsson G; Olsson AM; Luttrop W; Cekan Z; Purvis K; Diczfalusy E
Vitam Horm; 1975; 33():351-76. PubMed ID: 1229063
[TBL] [Abstract][Full Text] [Related]
6. Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients.
Karr JP; Wajsman Z; Kirdani RY; Murphy GP; Sandberg AA
J Urol; 1980 Aug; 124(2):232-6. PubMed ID: 7190620
[TBL] [Abstract][Full Text] [Related]
7. Hormonal effects of different doses of estramustine phosphate (Estracyt) in patients with prostatic carcinoma.
Fritjofsson A; Norlén BJ; Högberg B; Rajalakshmi M; Cekan SZ; Diczfalusy E
Scand J Urol Nephrol; 1981; 15(1):37-44. PubMed ID: 6787701
[TBL] [Abstract][Full Text] [Related]
8. Hormone changes in patients with prostatic carcinoma during treatment with estramustine phosphate.
Fosså SD; Fosså J; Aakvaag A
J Urol; 1977 Dec; 118(6):1013-8. PubMed ID: 926240
[TBL] [Abstract][Full Text] [Related]
9. Plasma hormone levels in patients with prostatic carcinoma treated with diethylstilboestrol and estramustine.
Bishop MC; Selby C; Taylor M
Br J Urol; 1985 Oct; 57(5):542-7. PubMed ID: 3904908
[TBL] [Abstract][Full Text] [Related]
10. Some effects of orchiectomy, oestrogen treatment and radiation therapy in patients with prostatic carcinoma.
Tomić R
Scand J Urol Nephrol Suppl; 1983; 77():1-37. PubMed ID: 6426040
[TBL] [Abstract][Full Text] [Related]
11. Metabolism of estramustine phosphate (Estracyt) in patients with prostatic carcinoma.
Andersson SB; Gunnarsson PO; Nilsson T; Forshell GP
Eur J Drug Metab Pharmacokinet; 1981; 6(2):149-54. PubMed ID: 7274309
[TBL] [Abstract][Full Text] [Related]
12. The influence of treatment with estrogens and estramustine phosphate on platelet aggregation and plasma lipoproteins in non-disseminated prostatic carcinoma.
Agardh CD; Nilsson-Ehle P; Lundgren R; Gustafson A
J Urol; 1984 Nov; 132(5):1021-4. PubMed ID: 6492270
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular complications of estrogen therapy for nondisseminated prostatic carcinoma. A preliminary report from a randomized multicenter study.
Lundgren R; Sundin T; Colleen S; Lindstedt E; Wadström L; Carlsson S; Hellsten S; Pompeius R; Holmquist B; Nilsson T
Scand J Urol Nephrol; 1986; 20(2):101-5. PubMed ID: 3529368
[TBL] [Abstract][Full Text] [Related]
14. Effect of treatment with diethylstilbestrol-polyestradiol phosphate or estramustine phosphate (estracyt) on natural killer cell activity in patients with prostatic cancer.
Kalland T; Haukaas S
Invest Urol; 1981 May; 18(8):437-9. PubMed ID: 7228576
[TBL] [Abstract][Full Text] [Related]
15. [Clinical effects of estramustine phosphate disodium (Estracyt) on prostatic cancer].
Nishio S; Kishimoto T; Maekawa M; Kawakita J; Hayahara N; Yuki K; Morikawa Y; Yasumoto R; Kato Y; Funai K
Hinyokika Kiyo; 1986 Nov; 32(11):1763-70. PubMed ID: 3825823
[TBL] [Abstract][Full Text] [Related]
16. The treatment of oestrogen-escaped carcinoma of the prostate with estramustine phosphate.
Chisholm GD; O'Donoghue EP; Kennedy CL
Br J Urol; 1977; 49(7):717-20. PubMed ID: 339986
[TBL] [Abstract][Full Text] [Related]
17. Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: a randomized multicenter study with 15 years of followup. The South Sweden Prostate Cancer Study Group.
Lundgren R; Nordle O; Josefsson K
J Urol; 1995 May; 153(5):1580-6. PubMed ID: 7714978
[TBL] [Abstract][Full Text] [Related]
18. Estramustine phosphate (Estracyt) in the treatment of prostatic carcinoma.
Könyves I
Int Urol Nephrol; 1989; 21(4):393-7. PubMed ID: 2693392
[TBL] [Abstract][Full Text] [Related]
19. Endocrine effects of oestrogen withdrawal in long-term treated patients with prostatic adenocarcinoma.
Tomić R; Damber JE; Bergman B
Eur Urol; 1988; 14(1):6-8. PubMed ID: 3342807
[TBL] [Abstract][Full Text] [Related]
20. DNA content in cells aspirated from carcinoma of the prostate treated with oestrogenic compounds.
Kjaer TB; Thommesen P; Frederiksen P; Bichel P
Urol Res; 1979 Dec; 7(4):249-51. PubMed ID: 524561
[No Abstract] [Full Text] [Related]
[Next] [New Search]
